Roche Holding AG (RHHVF)

Roche Backs Full-Year View as First-Half Sales Rise

Roche confirms full year targets as first-half sales fall

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip

EXEL Down on Colorectal Cancer Study Data on Zanzalintinib

U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche

FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL

FDA approves first generic version of Roche's flu drug

JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study

Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer

Nurix Therapeutics Deal With Roche Is Worth Betting On

Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know

Roche sticks to German investment after Eli Lilly cuts

Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript

Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial